Investigational drug · Phase 3
Afimkibart
Also called: RO7790121, RVT-3101, PF 06480605
Not approved by FDA. In 12 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
12
12 still active
All registered trials
13
Any phase or sponsor naming "Afimkibart"
First trial start
2023
Jul 24, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Afimkibart", any sponsor or status.
Conditions studied
As listed on its trial records.
- Moderately to Severely Active Ulcerative Colitis
- Moderately to Severely Active Crohns Disease
- Atopic Dermatitis
- Rheumatoid Arthritis
- Crohns Disease
Approved drugs for the same conditions: Rheumatoid arthritis · Atopic dermatitis (eczema) · Crohn's disease · Ulcerative colitis · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Afimkibart" as an intervention, largest first.
- A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06819878 · 600 participants (planned) · Start Mar 17, 2025 · Primary completion Dec 31, 2028
Drug: Afimkibart; Placebo · For: Moderately to Severely Active Crohns Disease
Sites: Dothan, Alabama; Phoenix, Arizona; Sun City, Arizona · 375 sites in all
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06819891 · 425 participants (planned) · Start May 12, 2025 · Primary completion Dec 31, 2028
Drug: Afimkibart; Placebo · For: Moderately to Severely Active Crohns Disease
Sites: Dothan, Alabama; Glendale, Arizona; Lancaster, California · 208 sites in all
- A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06589986 · 400 participants (planned) · Start Sep 17, 2024 · Primary completion Jan 30, 2027
Drug: Afimkibart; Placebo · For: Moderately to Severely Active Ulcerative Colitis
Sites: Dothan, Alabama; Lancaster, California; Orange, California · 184 sites in all
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06588855 · 350 participants (planned) · Start Dec 11, 2024 · Primary completion Oct 29, 2026
Drug: Afimkibart; Placebo · For: Moderately to Severely Active Ulcerative Colitis
Sites: Dothan, Alabama; Scottsdale, Arizona; Sun City, Arizona · 168 sites in all
- A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07846683 · 350 participants (planned) · Start Nov 15, 2026 · Primary completion May 31, 2028
Drug: Afimkibart; Placebo · For: Moderately to Severely Active Ulcerative Colitis
Sites: Cordova, Tennessee
- A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic DermatitisPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06863961 · 162 participants · Start Apr 1, 2025 · Primary completion Jul 22, 2026
Drug: Afimkibart; Placebo · For: Atopic Dermatitis
Sites: Fountain Valley, California; Los Angeles, California; Tampa, Florida · 52 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07137598 · 160 participants (planned) · Start Dec 5, 2025 · Primary completion Apr 17, 2027
Drug: Afimkibart; Placebo · For: Rheumatoid Arthritis
Sites: Avondale, Arizona; Peoria, Arizona; La Jolla, California · 66 sites in all
- An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid ArthritisPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07620392 · 120 participants (planned) · Start Jun 3, 2026 · Primary completion Jul 8, 2033
Drug: Afimkibart · For: Rheumatoid Arthritis
Sites: Tamarac, Florida; Lake Charles, Louisiana; Houston, Texas · 17 sites in all
- A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic DermatitisActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07223697 · 120 participants (planned) · Start Jan 8, 2026 · Primary completion Mar 1, 2033
Drug: Afimkibart · For: Atopic Dermatitis
Sites: Los Angeles, California; Tampa, Florida; Alpharetta, Georgia · 31 sites in all
- A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07298421 · 100 participants (planned) · Start Aug 18, 2026 · Primary completion May 31, 2030
Drug: Afimkibart · For: Moderately to Severely Active Crohns Disease
Sites: New York, New York; Harlingen, Texas; South Brisbane, Australia · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- TL1A-DR3 Signaling in Inflammatory Bowel Disease: From Pathogenesis to Therapeutic Targeting.
Tsuruta K, Yoshioka S, Takedatsu H · Kurume Med J 2026
- Targeting the TL1A pathway in inflammatory bowel disease: mechanistic insights and emerging therapeutic pipeline.
Quraishi MN, Jairath V, Al-Bawardy B · Inflamm Bowel Dis 2026
- Tumor necrosis factor-like cytokine 1ߙA antagonists for inflammatory bowel disease: A systematic review and meta-analysis.
Paudel MS, Sharma V, Bhattarai K, et al. · Indian J Gastroenterol 2026
- TL1A inhibitors in inflammatory bowel disease: A systematic review of phase 2 clinical trials.
Choi JG, Gong EJ, Bang CS, et al. · Saudi J Gastroenterol 2026
- Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries.
Gupte D, Suthar NR, MacDonald JK, et al. · Paediatr Drugs 2026
- Review Article: TL1A Inhibitors in IBD - Mechanistic Rationale and Clinical Evidence.
Goyal MK, Srivastava H, Sehgal T, et al. · Aliment Pharmacol Ther 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.